A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis
Josef S Smolen, Stanley B Cohen, Hans-Peter Tony, Morton Scheinberg, Alan Kivitz, Andra Balanescu, Juan Gomez-Reino, Liyi Cen, Peijuan Zhu, Tamas Shisha, Josef S Smolen, Stanley B Cohen, Hans-Peter Tony, Morton Scheinberg, Alan Kivitz, Andra Balanescu, Juan Gomez-Reino, Liyi Cen, Peijuan Zhu, Tamas Shisha
Abstract
Objectives: The aim of this report is to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) equivalence as well as similar efficacy, safety and immunogenicity between GP2013, a biosimilar rituximab, and innovator rituximab (RTX) in patients with rheumatoid arthritis (RA) with inadequate response or intolerance to tumour necrosis factor inhibitor (TNFi) treatment.
Methods: In this multinational, randomised, double-blind, parallel-group study, 312 patients with active disease despite prior TNFi therapy were randomised to receive GP2013 or either the EU (RTX-EU) or the US (RTX-US) reference product, along with methotrexate (MTX) and folic acid. The primary endpoint was the area under the serum concentration-time curve from study drug infusion to infinity (AUC0-inf). Additional PK and PD parameters, along with efficacy, immunogenicity and safety outcomes were also assessed up to week 24.
Results: The 90% CI of the geometric mean ratio of the AUCs were within the bioequivalence limits of 80% to 125% for all three comparisons; GP2013 versus RTX-EU: 1.106 (90% CI 1.010 to 1.210); GP2013 versus RTX-US: 1.012 (90% CI 0.925 to 1.108); and RTX-EU versus RTX-US: 1.093 (90% CI 0.989 to 1.208). Three-way PD equivalence of B cell depletion was also demonstrated. Efficacy, safety and immunogenicity profiles were similar between GP2013 and RTX.
Conclusions: Three-way PK/PD equivalence of GP2013, RTX-EU and RTX-US was demonstrated. Efficacy, safety and immunogenicity profiles were similar between GP2013 and RTX.
Trial registration number: NCT01274182; Results.
Keywords: B cells; DMARDs (biologic); Rheumatoid arthritis.
Conflict of interest statement
Competing interests: PZ, LC and TS are employees of Sandoz/Hexal. JSS, HPT, AK, AB, JG-R and MS received investigator fees from Sandoz, a Novartis Division.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Figures
References
- Rituxan® (rituximab) full Prescribing Information, Genentech, Inc. 2014.
- MabThera® SmPC.
- Schiestl M, Stangler T, Torella C, et al. . Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011;29:310–2.10.1038/nbt.1839
- McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther 2012;91:405–17.10.1038/clpt.2011.343
- Visser J, Feuerstein I, Stangler T, et al. . Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 2013;27:495–507.10.1007/s40259-013-0036-3
- da Silva A, Kronthaler U, Koppenburg V, et al. . Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013. Leuk Lymphoma 2014;55:1609–17.10.3109/10428194.2013.843090
- U.S. Food and Drug Administration. Clinical Pharmacology Data to support a demonstration of Biosimilarity to a Reference Product Guidance for industry. 2016. (accessed on 15 March 2017).
- Arnett FC, Edworthy SM, Bloch DA, et al. . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.10.1002/art.1780310302
- Felson DT, Anderson JJ, Boers M, et al. . American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.10.1002/art.1780380602
- Prevoo ML, van’t Hof MA, Kuper HH, et al. . Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.10.1002/art.1780380107
- Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23:S100.
- Ng CM, Bruno R, Combs D, et al. . Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005;45:792–801.10.1177/0091270005277075
- Breedveld F, Agarwal S, Yin M, et al. . Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007;47:1119–28.10.1177/0091270007305297
- Cohen SB, Emery P, Greenwald MW, et al. . Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793–806.10.1002/art.22025
- Yoo DH, Suh CH, Shim SC, et al. . A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2017;7610.1136/annrheumdis-2016-209540
- Williams JH, Hutmacher MM, Zierhut ML, et al. . Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximab. Br J Clin Pharmacol 2016;82:1568–79.10.1111/bcp.13094
- Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double.
- Cohen SB, Keystone E, Genovese MC, et al. . Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis 2010;69:1158–61.10.1136/ard.2009.119222
- Keystone EC, Cohen SB, Emery P, et al. . Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol 2012;39:2238–46.10.3899/jrheum.120573
- Yoo DH, Park W, Jeka S, et al. . A randomized, controlled, multicenter, 2-arm, parallel-group, double-blind study to demonstrate the equivalence of CT-P10 to innovator rituximab with respect to pharmacokinetic profile in patients with rheumatoid arthritis. Arthritis Rheum 2013;65:S736.
Source: PubMed